Analogously, growing evidences support the promising opportunity of combining epigenetic modulators that have previously shown activity in DLBCL with immune-checkpoint blockade [251], including inhibitors for EZH2 histone methyltransferase [252,253,254], G9a/DNMT methyltransferase [255,256], or histone deacetylases [102,257,258]. The gene discussed is EHMT2; the disease is diffuse large B-cell lymphoma.